SCHOTT Pharma : Presentation H1 2023/2024

Q2 / H1 2024 Results presentation

Andreas Reisse, CEO

Dr. Almuth Steinkühler, CFO

The fiscal year 2024 runs from October 2023 to September 2024.

Disclaimer

This presentation has been prepared solely for use at this meeting. This material is given in conjunction with an oral presentation and should not be taken out of context. By attending the meeting where this presentation is held or accessing this presentation, you agree to be bound by the following limitations.

This publication has been prepared by SCHOTT Pharma AG & Co. KGaA. It may contain statements which address such key issues as strategy, future financial results, events, competitive positions and product developments. Such forward-looking statements are subject to a number of risks, uncertainties and other factors, including, but not limited to those described in SCHOTT Pharma's disclosures, in particular in the chapter "Risks" in SCHOTT Pharma's annual report. Should one or more of these risks, uncertainties and other factors materialize, or should underlying expectations not occur or assumptions prove incorrect, actual results, performances or achievements of SCHOTT Pharma may vary materially from those described in the relevant forward-looking statements.

These statements may be identified by words such as "expect," "want," "anticipate," "intend," "plan," "believe," "seek," "estimate," "will," "project" or words of similar meaning. SCHOTT Pharma neither intends, nor assumes any obligation, to update or revise its forward-looking statements regularly in light of developments which differ from those anticipated. Stated competitive positions are based on management estimates supported by information provided by specialized external agencies.

Our financial reports, presentations, press releases and ad-hoc releases may include alternative financial metrics. These metrics are not defined in the IFRS (International Financial Reporting Standards). SCHOTT Pharma's net assets, financial position and results of operations should not be assessed solely on the basis of these alternative financial metrics. Under no circumstances do they replace the performance indicators presented in the consolidated financial statements and calculated in accordance with the IFRS. The calculation of alternative financial metrics may vary from company to company despite the use of the same terminology. Further information regarding the alternative financial metrics used at SCHOTT Pharma can be found on our web site (https://www.schott-pharma.com/investor-relations).

The information contained in this presentation is provided as of the date of this presentation and is subject to change without notice.

Due to rounding, individual numbers presented throughout this, and other documents may not add up precisely to the totals provided and percentages may not precisely reflect the absolute figures to which they refer.

For technical reasons, there may be differences in formatting between the accounting records appearing in this document and those published pursuant to legal requirements.

1 © SCHOTT Pharma AG & Co. KGaA

Internal

Strategy & Business Update

Andreas Reisse, CEO

© SCHOTT Pharma AG & Co. KGaA

Based on Q2 2024 results, SCHOTT Pharma is well on track to meet its full year guidance

Revenue1:	EBITDA margin1:	HVS share
EUR 247m (+11%)	27.0%	of 53% in H1 2024

Continued growth in revenue	Continued high profitability at	Consequent execution of
despite high basis of	constant currencies while covering	strategy to achieve the mid-
previous year	significant ramp-up costs	term target of 60% HVS share

1 At constant currencies

3 © SCHOTT Pharma AG & Co. KGaA

Internal

Robust market trends confirm growth strategy - Continued execution on shift to high-value solutions

Significant market opportunities

• GLP-1
• mRNA
• ADCs
• Subcutaneous administration
• Homecare
• Manufacturing transformation
• ...

Market

Shift to HVS

>60%

53%

	Innovation	48%
Trusted		39%
partner

Expansion

Strategy

FY22

FY23

H1 24

Mid-term

4 © SCHOTT Pharma AG & Co. KGaA

Internal

SCHOTT Pharma is innovating along the entire value

chain and major pharma megatrends		Innovation

Advancing large volume infusion

Collaboration with KORU Medical Systems to simplify subcutaneous drug administration

Addresses the market for treatments requiring recurring dosing regimens, e.g., chronic diseases or cancer

Broader functional service offering

One-stop shop for drug developers, covering full range of analytical tests needed for drug submission

Helps customers to accelerate the complex, time- and cost-intensive drug registration process and bring their products to market faster

Pioneering sustainability efforts

Collaborating with Big Pharma to transform industry and advance net zero transformation

Piloting secondary packaging recycling initiatives

5 © SCHOTT Pharma AG & Co. KGaA

Internal

Expansion projects on track: strengthening global presence with new production sites

Expansion

Inauguration of new state-of-the-art production

Successful recent start of commercial production of prefillable glass syringes in Lukacsházá, Hungary

Additional production capacity will support major pharma trends to safely store GLP-1 drugs, vaccines, and biologics

Further investments are planned to expand site

New site in the U.S., one of the strongest growth markets

Investment of USD 371m to increase manufacture capabilities for HVS

First U.S. manufacturing facility in Wilson, North Carolina, to fill demand for domestic supply of prefillable glass and polymer syringes

Groundbreaking expected for 2025

6 © SCHOTT Pharma AG & Co. KGaA

Internal

Financial Update

Dr. Almuth Steinkühler, CFO

© SCHOTT Pharma AG & Co. KGaA

Key financial figures for Q2 2024

RevenuesEBITDAMargin

EUR 247m (cc1)	11%	EUR 67m (cc1)	27.0%
EUR 234m (rep.)	5%	EUR 44m (rep.)	18.9%

CAPEX2		EPS
EUR 28m	- 5m	EUR 0.17	- 48%

1 At constant currencies; 2 Capex excluding leasing

8 © SCHOTT Pharma AG & Co. KGaA

Internal

Strong revenue growth despite high comparable base from previous year

Revenues1		DCS	DDS
EURm
		+9%
+11%		(cc2)
(cc2)	+4%
(rep.)	(rep.)	489
+5%
(rep.)	449
247
224

	96	155	200
72

151	151	294	290

Q2 23

Q2 242

H1 23

H1 242

1 Segment split excluding consolidation effects, 2 At constant currencies

9 © SCHOTT Pharma AG & Co. KGaA

Key developments

Strong demand for prefillable syringes and the ongoing expansion of capacities in DDS segment leads to further increase of HVS

DCS segment developed as expected and returned to high level of previous year despite the temporary destocking effect for vials on the customer side

Internal